This viral assay is part of the Respiratory Viral Panel and is not available on an individual basis. The Respiratory Viral Panel was cleared by the FDA for in vitro diagnostic use as a panel only and must be ordered in its entirety.
Adenoviruses, particularly subgroup C serotypes 1, 2, 5, and 6, are important causes of acute upper and lower respiratory tract illnesses, especially in infants, children, and immunocompromised patients. In immunocompromised patients, multiple localized infections can occur as a manifestation of disseminated infection from a single serotype.
See below for assay and pathogen-specific information. For online ordering methods click here or contact us.
The Respiratory Viral Panel is a comprehensive assay for the detection of a broad range of viruses and subtypes representing the majority of circulating respiratory disease-causing pathogens of particular importance to children, elderly, and immunocompromised patients. Detection of these pathogens will lead to more efficient management of patients with respiratory infections, play a key role in surveillance, and aid in limiting the spread of respiratory viruses through infection control practices.
Procedure
Viral nucleic acid is extracted from the specimen, which undergoes reverse transcription to generate complementary DNA (cDNA). The target cDNA is amplified using polymerase chain reaction (PCR), then analyzed with Luminex® xTag™ technology to detect the presence or absence of each virus in the panel. The Respiratory Viral Panel (RVP) has been cleared by the FDA for in vitro diagnostic use.
Specimen type & specimen handling
**Bronchial Lavage/Bronchial Wash: 2 mls collected in a sterile, screw top tube. Ship at ambient temperature Monday thru Friday. Specimen must be received within 96 hrs of collection.
Sputum: 2 mls collected in a sterile container, then transferred to sterile, screw top tube for shipment. Ship at ambient temperature Monday thru Friday. Specimen must be received within 96 hrs of collection.
**Throat Gargle: 2 mls collected in a sterile container then transferred to sterile, screw top tube for shipment. Ship at ambient temperature Monday thru Friday. Specimen must be received within 96 hrs of collection.
**Upper respiratory aspirate (NP aspirate, nasal aspirate/wash, tracheal aspirate, etc.): 2 mls collected in a sterile, screw top tube. Ship at ambient temperature Monday thru Friday. Specimen must be received within 96 hrs of collection.
Upper respiratory swab (*NP swab, **throat swab): Sterile swab placed in 2 ml sterile saline, M4, or viral transport media in a sterile, screw top tube. Do not use calcium alginate swab or wood shafted swab. Ship at ambient temperature Monday thru Friday. Specimen must be received within 96 hrs of collection.
CSF: 2 mls collected in a sterile, screw top tube. Freeze and ship on dry ice Monday thru Friday. Specimen must be received within 96 hrs of collection.
All suction-type collection devices are inappropriate for specimen transport. Transfer specimen into sterile, leakproof tube for transport.
Call ViraCor for authorization prior to sending any specimen type other than those listed above.
If another specimen type has received authorization for testing the following comment will appear in the final report: "The clinical utility of this result has not yet been demonstrated in the peer reviewed literature and is therefore unknown."
Causes for rejection
Specimens other than those listed above that were sent without prior authorization.
Wood shafted swab, calcium alginate swab.
Call ViraCor at 800-305-5198 if specimen is greater than 96 hrs old.
Specificity
Detects 12 Respiratory viral targets: respiratory syncytial virus (RSV) A, respiratory syncytial virus (RSV) B, influenza A, influenza A subtype H1, influenza A subtype H3, influenza B, parainfluenza 1, parainfluenza 2, parainfluenza 3, human metapneumovirus (hMPV), rhinovirus, and adenovirus.
Assay Range
Qualitative results (Positive/Not Detected) for: RSV A, RSV B, influenza A, influenza A subtype H1, influenza A subtype H3, influenza B, parainfluenza 1, parainfluenza 2, parainfluenza 3, hMPV, rhinovirus, and adenovirus.
Turnaround Time
Same day (within 12 to 18 hours of receiving specimen), Monday through Saturday
Shipping
Ship Monday through Friday. Friday shipments must be labeled for Saturday delivery. All specimens must be labeled with patient's name and collection date. Multiple tests can be run on one specimen.
Ship specimens FedEx Priority Overnight® to:
ViraCor Laboratories, 1001 NW Technology Dr, Lee's Summit, MO 64086
* NP swab has been cleared by the FDA for use in the RVP assay.
**In-house verification performed to establish as suitable specimen types.
CPT codes provided are based on ViraCor’s interpretation of the American Medical Association’s Current Procedural Terminology (CPT) codes and are provided for informational purposes only. CPT coding is the sole responsibility of the billing party. Questions regarding coding should be addressed to your local Medicare carrier. ViraCor assumes no responsibility for billing errors due to reliance on the CPT codes illustrated in this material. Information derived from Respiratory Viral Panel Package Insert (Luminex Corporation).
Respiratory Viral Panel is a product of Luminex Corporation. xTAG is a trademark of Luminex Corporation. Luminex is a registered trademark of Luminex Corporation.
0109 V3
Pathogen Overview
ABOUT ADENOVIRUS
Adenoviruses are members of the Adenoviridae family and are nonenveloped, double-stranded DNA viruses comprised of 6 subgroups, A through F, based on common biologic, morphologic, and genetic features. To date, 51 serotypes have been identified. Adenovirus was first isolated in 1953 from adenoid tissue-derived cell cultures, which were observed to spontaneously degenerate over time.
ADENOVIRUS CLINICAL MANIFESTATIONS
Viral infection may occur through direct contact, inhalation of respiratory droplets, or ingestion. After recovery from an active infection, a patient may harbor persistent infections in the tonsils, adenoids, other lymphoid tissues, or intestines. Some adenoviruses establish persistent, asymptomatic infections, and viral shedding may occur for years. Infection most commonly occurs during childhood.
Severe infections are caused primarily by subgroup C adenoviruses. Specific serotypes have been associated with particular diseases. For example, serotypes 40 and 41 are commonly associated with gastroenteritis, while subgroup C serotypes 1, 2, 5, and 6 are commonly associated with respiratory tract illnesses and conjunctivitis in children. In immunocompromised patients, however, multiple localized infections can occur as a manifestation of disseminated infection from a single serotype.
Severe morbidity and mortality due to adenovirus infection affect both hematopoietic stem cell transplant (HSCT) and solid organ transplant recipients. Common illnesses due to adenovirus infection include hemorrhagic cystitis/nephritis, pneumonitis, hepatitis, liver failure, and gastroenteritis, particularly during the acute post-transplant period prior to engraftment. Symptoms of adenovirus infection vary widely, depending on the organ involved. Adenovirus nephritis was associated with acute renal failure in 90% of infected patients. Graft-versus-host disease (GVHD) is also associated with adenovirus infection, and allograft failure may occur in solid organ transplant recipients. Mortality rates of 60% among patients with pneumonia and 50% of patients with hepatitis have been reported.
Retrospective studies of HSCT patients found the incidence of adenovirus infection ranging from 4 to 20%, with similar percentages developing into invasive disease. However, among patients with T cell depleted or mismatched allografts, the infection rate increased to between 20 and 30%, with 30 to 40% of those patients developing invasive disease. This research confirms other reports that found T cell depletion of a graft was associated with a higher incidence of adenovirus infection after transplantation. Polymerase chain reaction (PCR) assays used to detect adenovirus DNA in peripheral blood have demonstrated a strong correlation between viremia and the risk of disseminated adenovirus disease.
Adenovirus infections are particularly associated with significant rates of morbidity and mortality in children who undergo HSCT. In one retrospective study of 328 pediatric HSCT recipients, 37 (11.3%) were infected with adenovirus within 6 months of the transplant procedure. Infection with adenovirus delayed recovery of immunity after HSCT, and infection resulted in 7 deaths (2.1% mortality). Another retrospective study found that over a 4-year period, 42 of 201 HSCT patients (21%) had positive adenovirus cultures post-transplant. The incidence of infection was significantly higher in pediatric patients than in adults. Pediatric patients also had an earlier onset of infection, averaging less than 30 days after transplantation, compared with an average onset of 90 days among adults. Moderate to severe acute GVHD and isolation of adenovirus from 2 or more sites were significant risk factors for developing adenovirus disease.
LABORATORY DIAGNOSIS
Several methods can be used to detect adenoviruses in patients, including virus isolation, serology, and molecular amplification methods, such as PCR. However, not all methods are appropriate for testing transplant recipients. Rates of seroconversion to adenoviruses are high because individuals commonly contract adenoviruses during childhood. Therefore, serology has limited diagnostic value in a clinical setting. Virus isolation through cell culture techniques is a slow process, often taking days to weeks for completion, limiting the clinical usefulness. Furthermore, virus isolation is technically demanding and requires careful sample handling to preserve virus infectivity and, thus, can have low diagnostic sensitivity and yield false negative results. Isolation of viruses may be particularly complicated in immunocompromised patients who have received transfusions of blood products that contain adenovirus antibodies. Additionally, virus isolation does not yield quantitative results, which limits the usefulness of cell culture isolation in monitoring the clinical progress of patients following treatment.
In contrast to these methods, PCR techniques are fast, and extremely sensitive and can identify adenoviruses using many different types of clinical specimens, such as whole blood, urine, cerebrospinal fluid, lung tissue, bone marrow aspirate, throat specimens and fecal specimens, among other fluids and tissues. Quantitative, real-time PCR allows accurate quantification of viral genomic DNA over a range of fewer than 10 copies to as many as 107 copies. These methods are rapid; results can be provided within 24 hours of specimen receipt. This approach provides a substantial advantage over other methods, since patients with viral loads over 106 copies/ ml of adenovirus are considered to be at increased risk for fatal complications. In addition to providing early detection, real-time PCR can also be used to monitor infection progression and response to therapy.
TREATMENT
No specific antiviral therapy has been shown to produce a definite clinical effect against adenovirus infection. The efficacy of ribavirin and cidofovir are under evaluation; vidarabine has been associated with poor outcomes. If antiviral therapy is used, it should be initiated early in the clinical course and used with restraint to avoid hematologic toxicity and nephrotoxicity associated with these therapies. High-dose intravenous immunoglobulin (IVIG) treatment has been successfully used to treat some patients, and donor leukocyte transfusions for solid organ transplant recipients may be useful as adjunctive treatment with antiviral therapy. Standardized treatment guidelines for transplant recipients have not been developed; treatment decisions should be made on an individual basis. Careful monitoring of viral load during treatment is necessary for optimal outcomes.
CONCLUSION
Although adenovirus can produce severe illness in transplant recipients, sensitive, rapid, quantitative, real-time PCR techniques can quickly and accurately identify the virus. This method allows early diagnosis and differentiation from other infections, giving patients the best chance for recovery. Early diagnosis and intervention provides the best chance of reducing the risk of illness and death among transplant recipients. Real-time PCR may provide the most effective means of detecting adenovirus infection early so that preemptive therapy can be administered.
Selected References
Bruno B, Zager RA, Boeckh MJ, et al. Adenovirus nephritis in hematopoietic stem-cell transplantation. Transplantation. 2004;77(7):1049-57.
Claas EC, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol. 2005;43(4):1738-1744.
Echavarria M, Sanchez JL, Kolavic-Gray SA, et al. Rapid detection of adenovirus in throat swab specimens by PCR during respiratory disease outbreaks among military recruits. J Clin Microbiol. 2003;41(2):810-812.
Flomenberg P, Babbitt J, Drobyski WR, et al. Increasing incidence of adenovirus disease in bone marrow transplant recipients. J Infect Dis. 1994;169(4):775-781.
Knipe D, Howley P. Fields Virology. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2006. Suparno C, Milligan DW, Moss PA, Mautner V. 2004. Adenovirus infections in stem cell transplant recipients: recent developments in understanding of pathogenesis, diagnosis and management. Leuk Lymphoma. 2004;45(5):873-885.
Van Tol MJ, Kroes AC, Schinkel J, et al. Adenovirus infection in pediatric stem cell transplant recipients: increased risk in young children with a delayed immune recovery. Bone Marrow Transplant. 2005;36(1):39-50.
PAO-01-0707 PCR tests are performed pursuant to a license agreement with Roche Molecular Systems, Inc.
Abstracts & Publications
Carrigan DR. Adenovirus infections in immunocompromised patients. Am J Med. 1997;102(3A):71-74.
Adenovirus infections have been reported in as many as one-fifth of bone marrow transplant (BMT) recipients and patients with acquired immunodeficiency syndrome (AIDS), and in a lesser, though still prominent, proportion of organ transplant recipients. The relative contributions of primary infections versus reactivations from latency in immunocompromised patients remain unclear. Compared with adult BMT recipients, pediatric BMT recipients appear to be infected by adenovirus more frequently and earlier in the post-transplant period. The diagnosis of adenovirus infection is complicated by the existence of >40 viral serotypes, although certain subgroups are more likely to be involved in certain patient populations. Adenoviruses are responsible for a broad range of clinical diseases that may be associated with high mortality, including pneumonia, hepatitis, encephalitis, hemorrhagic cystitis, and gastroenteritis. The clinical and histopathologic features of adenovirus disease may resemble those of cytomegalovirus disease, potentially complicating the diagnosis. Risk factors for clinical adenovirus disease include the number of sites from which the virus is cultured and, in BMT recipients, the presence of moderate to severe acute graft-versus-host disease.
Echavarria M, Forman M, van Tol MJD, Vossen JM, Charache P, et al. Prediction of severe disseminated adenovirus infection by serum PCR. Lancet. 2001;(358):384-385.
Adenoviruses are increasingly recognized as viral pathogens that can cause fatal infections in Immunocompromised patients, particularly recipients of haematopoietic stem-cell grafts. Adenovirus infections are not easily diagnosed and the development of a severe infection cannot be predicted by standard culture techniques. In a pilot study, we investigated the value of adenovirus DNA detection in serum as a marker of disseminated disease in 14 patients with defined patterns of adenovirus infections. The results show that the appearance of adenoviral DNA in serum preceded the development of a severe or fatal adenovirus infection. Because proper management is dependent on early diagnosis and differentiation from other conditions, this test may be a valuable tool in the management of adenovirus infection.
Hale PA, Heslop HE, Krance RA, et al. Adenovirus infection after pediatric bone marrow transplantation. Bone Marrow Transplant. 1999;(23):277-282.
Retrospective analysis of 206 patients undergoing 215 consecutive bone marrow transplants (BMT) at St. Jude's Children's Research Hospital between November 1990 and December 1994 identified 6% (seven male, six female) with adenovirus infection. The affected patients had a median age of 7.9 years (range 3-24 years) at time of transplantation. Although transplants were performed for hematologic malignancies, solid tumors or non-malignant conditions, only patients with hematologic malignancies had adenoviral infections. Adenovirus was first detected at a median of 54 days (range -4 to +333) after BMT. Adenovirus developed in eight of 69 (11.6%) of patients receiving grafts from matched unrelated or mismatched related donors, in four of 52 (7.7%) receiving grafts from HLA-matched siblings, and in one of 93 (1.1%) receiving autografts. The most common manifestation of adenovirus infection was hemorrhagic cystitis, followed by gastroenteritis, pneumonitis and liver failure. The incidence of adenovirus infection in pediatric BMT patients at our institution is similar to that reported in adult patients. Using univariate analysis, use of total body irradiation and type of bone marrow graft were significant risk factors for adenovirus infection. Only use of total body irradiation remained as a factor on multiple logistic regression analysis.
La Rosa AM, Champlin RE, Mirza N, et al. Adenovirus infections in adult recipients of blood and marrow transplants. Clin Infect Dis. 2001;(32):871-876.
Adenoviruses are increasingly recognized pathogens that affect blood and marrow transplant (BMT) recipients. Experience with 2889 adult BMT recipients were reviewed to study the incidence, clinical spectrum, risk factors for dissemination, response to therapy, and outcome of adenovirus infections. Eighty-five patients (3%) were diagnosed by means of culture (n-85) or culture and histopathological examination (n=6). Nine patients had asymptomatic viruria, and 76 had symptomatic infections, which included upper respiratory tract infection (n=20), enteritis (n=18), hemorrhagic cystitis (n=10), pneumonia (n=15), and disseminated disease (n=13). The overall mortality rate was 26%. A higher mortality rate was observed among patients with pneumonia (73%) and disseminated disease (61%). Risk factors for dissemination included receipt of an allogenic transplant, presence of graft-versus-host disease (GVHD), and receipt of concurrent immunosuppressive therapy. Intravenous ribavarin was not associated with an appreciable benefit among 12 patients who received this treatment. In conclusion, adenovirus infections are an important cause of morbidity and mortality in adult BMT recipients, particularly allogeneic transplant recipients with GVHD who are receiving immunosuppressive therapy. The need for an effective, nontoxic antiviral therapy is apparent.
Manna P, Arnoldi S, Vats A, Skopec J, Brewer J, Flomenberg P. Clinical role of quantitative viral load monitoring for adenovirus in immunocompromised patients. Poster presented at: American Society for Blood and Marrow Transplantation; February 16, 2004.
Munoz FM, Piedra PA, Demmier GJ. Disseminated adenovirus disease in immunocompromised and immunocompetent children. Clin Infect Dis. 1998;(27):1194.
A retrospective review of adenovirus infections at Texas Children's Hospital during 1990-1996 was performed to evaluate the epidemiology, clinical course, management, and outcome of disseminated adenovirus disease (DAD) in children. DAD with multiorgan involvement occurred in 11 (2.5%) of 440 adenovirus-infected patients. Six (54%) of the 11 were Immunocompromised and 5 (45%) were Immunocompetent. Mortality was 83% among the immunodeficient, 60% in the Immunocompetent, and 73% overall. Two (28%) of the 7 patients receiving Immunoglobulins with or without antivirals and 3 (75%) of the 4 not treated died of DAD. DAD was caused by particular serotypes (3, 5 and 7) and occurred at a younger age in Immunocompetent children. Viremia and prolonged viral excretion were more common in the Immunocompromised. Clinical features and outcome were similar in both groups. Prospective studies addressing the use of new antiviral agents, combination antiviral therapy, and preventive strategies are necessary to determine the optimal therapeutic approach for patients with DAD.
